|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Stanley M. Bergman||Exec. Chairman & CEO||3,51M||N/D||1950|
|Mr. James P. Breslawski||Vice Chairman & Pres||1,39M||N/D||1954|
|Mr. Steven Paladino||Exec. VP, CFO & Exec. Director||1,38M||N/D||1957|
|Mr. Gerald A. Benjamin||Exec. VP, Chief Admin. Officer & Director||1,38M||N/D||1953|
|Mr. Mark E. Mlotek||Exec. VP, Chief Strategic Officer & Director||1,29M||N/D||1956|
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners, and animal health clinics. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners. The company was founded in 1932 and is headquartered in Melville, New York.
L'ISS Governance QualityScore di Henry Schein, Inc. al 4 ottobre 2019 è 8. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 10; diritti degli azionisti: 7; retribuzione: 3.